Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifens anticancer activity. The study appears in the June 16 issue of the Journal of the National Cancer Institute.
Although adjuvant tamoxifen can reduce the risk of death for women with invasive breast cancer by about 15% over 10 to 15 years, many women do not receive any benefit from the drug. Even among patients most likely to benefit from tamoxifen--those with tumors that express the drugs target, the estrogen receptor (ER)--only 40% to 50% actually benefit. Studies have shown that patients with ER-positive tumors that express high levels of HER2/neu and the ER coactivator AIB1 often develop tamoxifen resistance, but the mechanism of the resistance has not been identified.
To find this mechanism, Rachel Schiff, Ph.D. and C. Kent Osborne, M.D., of the Baylor College of Medicine in Houston, and colleagues studied molecular interactions in breast cancer cells that expressed high levels of both HER2 and AIB1. They found that, in these cells, tamoxifen acted like an estrogen agonist and stimulated tumor growth. However, when the breast cancer cells were treated with the receptor tyrosine kinase inhibitor gefitinib, tamoxifen once again acted as an estrogen antagonist and tumor growth was blocked.
"Our data imply that monotherapy with growth factor pathway inhibitors like gefitinib may have little or only modest benefits on ER-positive, HER2-overexpressing breast cancer, but the results do provide a strong rationale for combining tamoxifen with gefitinib or other EGFR/HER2 pathway inhibitors to overcome … resistance in such tumors. Clinical trials of this new strategy are under way," the authors write.
In an editorial, Daniel F. Hayes, M.D., of the University of Michigan Health System in Ann Arbor, reviews tamoxifens potential for both harm and good in breast cancer patients. "It is imperative that we now take advantage of the advances in understanding of the biology of these … systems to efficiently select optimal treatment and even further reduce mortality of patients with breast cancer," he writes, adding that "[t]hese steps can only be taken by conducting well-designed clinical trials."
Sarah L. Zielinski | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...